Cassava Sciences under SEC probe for manipulating Alzheimer’s drug data

The U.S. Securities & Exchange Commission (SEC) has begun an investigation into Cassava Sciences (NASDAQ:SAVA) whether the company has manipulated study results for its investigational Alzheimer’s drug, The Wall Street Journal reported citing people familiar with the matter.